Class Action Notification: Levi & Korsinsky LLP has notified investors in Telix Pharmaceuticals Ltd. of a class action lawsuit aimed at recovering losses incurred due to alleged securities fraud between February 21, 2025, and August 28, 2025.
False Statement Allegations: The complaint alleges that defendants materially overstated the progress of prostate cancer therapeutic candidates and misrepresented the quality of Telix's supply chain and partners, leading to a misleading perception of the company's business and prospects.
Investor Rights Protection: Affected investors have until January 9, 2026, to request to be appointed as lead plaintiff, allowing them to share in any recovery without incurring out-of-pocket costs or fees to participate.
Law Firm Background: With over 20 years of experience in securities litigation, Levi & Korsinsky has secured hundreds of millions for aggrieved shareholders and is consistently ranked among the top securities litigation firms in the U.S., showcasing its expertise in complex cases.
TLX
$7.81+Infinity%1D
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
